Inventor · disambiguated record
Stefano Fiorucci
Also filed as: FIORUCCI STEFANO
16 granted patents·10 pending applications·159 citations·filing 2005–2025
93Inventor score
Files withINTERCEPT PHARMACEUTICALS INC7ANTIBE THERAPEUTICS INC3WALLACE JOHN L3BAR PHARMACEUTICALS S R L2BAR PHARMACEUTICALS SOC A RESPONSABILITA LIMITATA2
Top patents by PatentIndex Score
26 records- 0196US9763964B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2015·Granted Sep 19, 2017·23 cites·7 claims
- 0294US7932244B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2007·Granted Apr 26, 2011·24 cites·8 claims
- 0394US7910568B2Derivatives of 4- or 5-aminosalicylic acidANTIBE THERAPEUTICS INC·Filed 2006·Granted Mar 22, 2011·55 cites·17 claims
- 0492US7858608B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2009·Granted Dec 28, 2010·21 cites·5 claims
- 0589US8546365B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsPELLICCIARI ROBERTO·Filed 2011·Granted Oct 1, 2013·10 cites·18 claims
- 0684US9498484B2Treatment of fibrosis using FXR ligandsFIORUCCI STEFANO·Filed 2005·Granted Nov 22, 2016·8 cites·8 claims
- 0783US7498355B2Derivatives of 4- or 5-aminosalicylic acidANTIBE THERAPEUTICS INC·Filed 2006·Granted Mar 3, 2009·6 cites·8 claims
- 0881US10407462B2Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseasesBAR PHARMACEUTICALS S R L·Filed 2015·Granted Sep 10, 2019·7 cites·11 claims
- 0981US9090652B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2013·Granted Jul 28, 2015·3 cites·9 claims
- 1073US8114858B2Derivatives of 4- or 5-aminosalicylic acidWALLACE JOHN L·Filed 2010·Granted Feb 14, 2012·2 cites·10 claims
- 1170US10987362B2Treatment of fibrosis using FXR ligandsINTERCEPT PHARMACEUTICALS INC·Filed 2018·Granted Apr 27, 2021·0 cites·5 claims
- 1269US2025345374A1Methods for treating inflammatory bowel disease using bacillus amyloliquefaciensORMENDES SA·Filed 2025·Application pending·0 cites
- 1365US7879827B2Derivatives of 4- or 5-aminosalicylic acidANTIBE THERAPEUTICS INC·Filed 2009·Granted Feb 1, 2011·0 cites·6 claims
- 1462US2021346400A1Treatment of fibrosis using fxr ligandsINTERCEPT PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1559US2022160794A1Use of bacillus amyloliquefaciens and/or bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions, compositions thus obtained, and related methodORMENDES SA·Filed 2020·Application pending·0 cites
- 1655US2025367215A1Pharmaceutical combination comprising a cholane derivative and a statin or ursodesoxycholic acidBAR PHARMACEUTICALS SOC A RESPONSABILITA LIMITATA·Filed 2023·Application pending·0 cites
- 1751US10258633B2Treatment of fibrosis using FXR ligandsFIORUCCI STEFANO·Filed 2016·Granted Apr 16, 2019·0 cites·6 claims
- 1850US8114857B2Derivatives of 4- or 5-aminosalicylic acidWALLACE JOHN L·Filed 2010·Granted Feb 14, 2012·0 cites·5 claims
- 1950US2023357159A1Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptorsPREC BIO THERAPEUTICS S R L·Filed 2021·Application pending·0 cites
- 2048US11117926B2Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseasesBAR PHARMACEUTICALS S R L·Filed 2019·Granted Sep 14, 2021·0 cites·15 claims
- 2146US2023066156A16-substituted, 22-cyano hyodeoxycholanic analogues and uses thereofPREC BIO THERAPEUTICS S R L·Filed 2020·Application pending·0 cites
- 2246US2007179094A1Modulation of MDL-1 activity for treatment of inflammatory diseaseBAYER SCHERING PHARMA AG·Filed 2007·Application pending·0 cites
- 2346US2008119439A1Treatment and prevention of intestinal fibrosisBAYER SCHERING PHARMA AG·Filed 2007·Application pending·0 cites
- 2443US11332450B2Isoxazole as FXR receptor agonistsBAR PHARMACEUTICALS SOC A RESPONSABILITA LIMITATA·Filed 2019·Granted May 17, 2022·0 cites·7 claims
- 2543US2006252670A1Method of reducing drug-induced adverse side effects in a patientINTERCEPT PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 2642US2006270635A1Derivatives of 4- or 5-aminosalicylic acidWALLACE JOHN L·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →